Cargando…

siAKR1C3@PPA complex nucleic acid nanoparticles inhibit castration-resistant prostate cancer in vitro

INTRODUCTION: AKR1C3, as a crucial androgenic enzyme, implicates the androgen biosynthesis and promoting prostate cancer cell growth in vitro. This study provides a new gene therapy strategy for targeting AKR1C3 to treat castration-resistant prostate cancer. METHODS: siAKR1C3@PPA is assembled from P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Xiaoli, Yao, Zhou, Zhao, Tianyu, Guo, Jiahui, Ding, Jipeng, Zhang, Siwei, Liang, Zuowen, Wei, Zhengren, Zoa, Alexis, Tian, Yuantong, Li, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800608/ https://www.ncbi.nlm.nih.gov/pubmed/36591491 http://dx.doi.org/10.3389/fonc.2022.1069033

Ejemplares similares

Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer
por: Cui, Xiaoli, et al.
Publicado: (2023)

AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638
por: Zhou, Wen, et al.
Publicado: (2014)

Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3
por: Yu, Xiaoping, et al.
Publicado: (2023)

The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
por: Yin, Yarong Diana, et al.
Publicado: (2014)

PPA1, an energy metabolism initiator, plays an important role in the progression of malignant tumors
por: Wang, Shuying, et al.
Publicado: (2022)

Research on Performance of SBS-PPA and SBR-PPA Compound Modified Asphalts
por: Wei, Jianguo, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression
por: Tian, Yuantong, et al.
Publicado: (2014)

Princeton: PPA close down
Publicado: (1972)

Princeton : Fermeture du PPA
Publicado: (1972)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
por: Kim, In-Wha, et al.
Publicado: (2019)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Epiregulin expression and secretion is increased in castration-resistant prostate cancer
por: Wiesehöfer, Marc, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
por: Di Nunno, Vincenzo, et al.
Publicado: (2018)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Efficient PPA-SiO(2)-catalyzed Synthesis of β-enaminones Under Solvent-Free Conditions
por: Nisar, Muhammad, et al.
Publicado: (2013)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
por: Mitsui, Yozo, et al.
Publicado: (2023)

Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer
por: Pollard, Bette S., et al.
Publicado: (2019)

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer
por: Pak, Sahyun, et al.
Publicado: (2020)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
por: Cong, Xiaonan, et al.
Publicado: (2021)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Castration-resistant prostate cancer with metastasis to external auditory canal – Case report
por: Akagi, Naoki, et al.
Publicado: (2022)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lhdsq6sr95fsh3rtpdllsm8rmv